Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Christopher J. Sobecki bought 99,249 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was acquired at an average cost of $2.41 per share, with a total value of $239,190.09. Following the transaction, the director now owns 13,645 shares of the company’s stock, valued at $32,884.45. The purchase was disclosed in a filing with the SEC, which is available at this link.
LXRX opened at $3.45 on Friday. Lexicon Pharmaceuticals, Inc. has a 1 year low of $1.13 and a 1 year high of $11.51. The stock has a fifty day moving average price of $1.58 and a 200 day moving average price of $4.92.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.13). The company had revenue of $9.68 million during the quarter, compared to analysts’ expectations of $28.52 million. The company’s revenue was down 29.9% on a year-over-year basis. During the same period last year, the firm posted ($0.33) earnings per share. As a group, analysts predict that Lexicon Pharmaceuticals, Inc. will post 0.69 earnings per share for the current year.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. GSA Capital Partners LLP boosted its position in Lexicon Pharmaceuticals by 217.5% during the second quarter. GSA Capital Partners LLP now owns 87,132 shares of the biopharmaceutical company’s stock valued at $548,000 after purchasing an additional 59,685 shares during the last quarter. Clearbridge Investments LLC boosted its position in Lexicon Pharmaceuticals by 3.4% during the first quarter. Clearbridge Investments LLC now owns 1,292,130 shares of the biopharmaceutical company’s stock valued at $7,184,000 after purchasing an additional 42,540 shares during the last quarter. Wedbush Securities Inc. boosted its position in Lexicon Pharmaceuticals by 33.0% during the second quarter. Wedbush Securities Inc. now owns 194,339 shares of the biopharmaceutical company’s stock valued at $1,222,000 after purchasing an additional 48,182 shares during the last quarter. Pinnacle Associates Ltd. boosted its position in Lexicon Pharmaceuticals by 1.8% during the first quarter. Pinnacle Associates Ltd. now owns 550,549 shares of the biopharmaceutical company’s stock valued at $3,061,000 after purchasing an additional 9,615 shares during the last quarter. Finally, Wealth & Pension Services Group Inc. acquired a new stake in Lexicon Pharmaceuticals during the first quarter valued at $60,000. 98.87% of the stock is owned by hedge funds and other institutional investors.
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
Read More: Quantitative Easing
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.